[HTML][HTML] Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

M Myerson, C Ngai, J Jones, S Holleran… - Journal of lipid …, 2005 - ASBMB
HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of
dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-
blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80
mg/day, on plasma lipid and lipoprotein levels and on the metabolism of apolipoprotein B
(apoB) in VLDL, intermediate density lipoprotein (IDL), and LDL and of triglycerides (TGs) in
VLDL. Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL …